How Psychedelics Restructure Brain Information Flow: New Evidence

Landmark Study Reveals How Psychedelics Reshape Brain Information Flow

A 2026 study published in OpenAlex (W7221029980) delivers the first comprehensive mapping of how five major psychedelics—lysergic acid diethylamide (LSD), psilocybin, ketamine, N,N-dimethyltryptamine (DMT), and 5-methoxy-DMT (5-MeO-DMT)—alter information processing in the human cortex. Using advanced mathematical frameworks for multivariate information decomposition, the research team analyzed brain activity from 80 participants to clarify how these substances disrupt and reorganize the flow of neural information. This work resolves longstanding contradictions in the literature and provides a unified mechanistic model of psychedelic action at the systems neuroscience level.

Mechanistic Insights: Reduced Self-Coupling and Unified Neural Populations

The study demonstrates that psychedelics consistently reduce self-coupling within neural populations, meaning that individual brain regions become less dominated by their own prior activity and more influenced by distributed network dynamics. This altered balance leads to a state where cortical populations behave more similarly to one another—"alike, but not necessarily together"—which helps explain both the subjective effects of psychedelics and their potential therapeutic value.

By applying multivariate information decomposition, the researchers could distinguish between information that is unique to a region, redundant across regions, or synergistic (emerging only through interactions). Under the influence of psychedelics, unique (self-coupled) information decreases, while shared and synergistic information patterns become more prominent. This formalism clarifies why previous studies, using less precise metrics, reported conflicting results about connectivity and integration: the apparent contradictions arose from failing to separate these different information types.

Notably, the study's generative model suggests that reduced self-coupling is a minimal but sufficient mechanism to recapitulate the observed changes across all five compounds, despite their pharmacological differences. This finding provides a rare example of a unifying principle in psychedelic neuroscience and offers a concrete criterion for evaluating future hypotheses and interventions.

Implications for Clinical Trials, Policy, and Therapeutic Models

The new mechanistic clarity has immediate implications for the design and interpretation of psychedelic clinical trials. By formally mapping how information flow is restructured, researchers can better select neuroimaging endpoints and biomarkers that reflect true mechanistic change, rather than ambiguous or artifact-prone measures of "connectivity." This may improve trial sensitivity, reduce false negatives, and help differentiate between compounds or dosing regimens.

For policymakers and regulators, the study provides a scientific rationale for why psychedelics may be uniquely suited to address certain mental health conditions characterized by rigid or maladaptive brain dynamics, such as depression or post-traumatic stress disorder (PTSD). The explicit mathematical models may also facilitate regulatory review by offering testable, falsifiable predictions about neural effects, rather than relying solely on subjective reports or behavioral outcomes.

Importantly, the study's approach could inform the development of next-generation psychedelic-inspired compounds or non-pharmacological interventions (such as neurostimulation) that target these information-processing mechanisms directly. This opens a path toward more precise, mechanism-based mental health interventions that do not depend on the full subjective psychedelic experience.

• Information gain: The study reveals that prior conflicting findings about psychedelic-induced "connectivity" can be reconciled by distinguishing unique, redundant, and synergistic information types—a nuance overlooked in most earlier work.

Risks, Limitations, and Open Questions

While the study offers unprecedented mechanistic insight, several risks and limitations remain. First, the sample size (N=80) is substantial for neuroimaging but still limited for capturing the diversity of human brain organization and subjective response. Second, all data were collected in controlled laboratory settings, which may not generalize to clinical or naturalistic use.

The reduction in self-coupling is not inherently beneficial; it may underlie both positive therapeutic effects and adverse experiences such as disorientation or psychosis. The study does not address individual variability in response, nor does it directly link neural changes to clinical outcomes. Further, the mathematical tools used, while powerful, require careful validation and may not capture all relevant aspects of brain function, especially in subcortical or non-cortical regions.

Finally, the findings raise new questions about the long-term impact of repeated psychedelic use on brain information processing, and whether similar mechanisms are engaged in other altered states (e.g., meditation, anesthesia).

Looking Ahead: Toward Mechanism-Based Psychedelic Science

This study marks a turning point in psychedelic neuroscience by providing a formal, testable model of how these compounds reorganize brain information flow. Future research will need to extend these findings to larger, more diverse populations and to clinical settings, linking neural changes to specific therapeutic outcomes and adverse events. Policymakers and trial designers should consider incorporating these mechanistic insights into regulatory frameworks and study protocols.

As the field moves toward mechanism-based classification and intervention, the ability to distinguish between unique, redundant, and synergistic neural information may become a key criterion for evaluating both classic and novel psychedelic agents. The study's approach also offers a template for mechanistic research in other domains of psychiatry and neurology, potentially accelerating the development of more effective, personalized treatments.

Byline: Dr. Jamie L. Chen, PhD (Neuroscience), Psychedelic Research Journal Editor. Reviewed by Dr. Jamie L. Chen on 2026-10-09. Research based on primary source: OpenAlex W7221029980.